HER2-Positive Breast Cancer
-10%
portes grátis
HER2-Positive Breast Cancer
;
Elsevier - Health Sciences Division
08/2018
264
Mole
Inglês
9780323581226
15 a 20 dias
Descrição não disponível.
Background/testing 1. The HER2 alteration in breast cancer 2. HER2 testing in the era of changing guidelines Advanced Disease 3. Optimal first-line treatment of HER2+ advanced disease 4. Second line therapy and beyond 5. HER2+ CNS metastases Therapeutics 6. Neoadjuvant therapy 7. Adjuvant therapy 8. Outcomes based on HR status in early stage disease 9. De-escalation of therapy for small tumor Toxicity considerations 10. Cardiac toxicity of HER2-targeted regimens 11. Non-cardiac toxicity of HER2-targeted therapy Therapies on the horizon 12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc) 13. Harnessing the immune system in HER2+ disease 14. Biosimilars
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Background/testing 1. The HER2 alteration in breast cancer 2. HER2 testing in the era of changing guidelines Advanced Disease 3. Optimal first-line treatment of HER2+ advanced disease 4. Second line therapy and beyond 5. HER2+ CNS metastases Therapeutics 6. Neoadjuvant therapy 7. Adjuvant therapy 8. Outcomes based on HR status in early stage disease 9. De-escalation of therapy for small tumor Toxicity considerations 10. Cardiac toxicity of HER2-targeted regimens 11. Non-cardiac toxicity of HER2-targeted therapy Therapies on the horizon 12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc) 13. Harnessing the immune system in HER2+ disease 14. Biosimilars
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
